Individual responses to semaglutide vary based on genetics, metabolism, and your body's specific peptide-pathway sensitivities
Conclusions The present review elucidates the physiological benefits of synthetic incretin-based medications, highlighting both their unprecedented clinical efficacy against T2D and obesity and their extensive non-target metabolic benefits against heart, kidney, and liver diseases
PMID: 24791752
When you take these medications, you lose both fat and lean mass, and when you have weight recurrence, you tend to gain fat mass back more than lean mass, Harris said
alternative-therapies.com PubMed Selective good angiogenesis, blocks bad angiogenesis (evidence: context dependent rodent preclinical modulation, unvalidated in humans)